Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAA868 dose-ranging versus apixaban in atrial fibrillation
2017-002741-29Phase 2Suspended
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abelacimab in Atrial fibrillation (AFib) (4 arms), sponsored by Novartis. Primary endpoint: Primary: FXI inhibition ≥80% at trough after 3 months of MAA868. Started Dec 2017; status: suspended.
02
Drugs
abelacimab
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2017-002741-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002741-29.